Past Performers - Life Sciences

Ablynx NV
Ghent, Belgium
Ablynx is a biopharmaceutical company working on a novel class of therapeutics, called Nanobodies®. Nanobodies® are single domain antibodies that appear to have the affinity and selectivity of traditional antibodies but are much smaller in size. This latter property potentially gives Nanobodies® several advantages over regular antibodies. The Company has a rich and diverse pipeline. Ablynx is a public company trading on NYSE-Euronext Brussels (ticker: ABLX).
Adolor Corporation
Exton, PA
Founded in 1994, Adolor Corporation (Nasdaq: ADLR) is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. The overall goal of the company's research effort is to develop products which maintain or improve opioid-like pain relief while reducing or eliminating opioid side effects.
Aegerion Pharmaceuticals, Inc.
Bridgewater, NJ
Aegerion Pharmaceuticals is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical products to treat cardiovascular and metabolic diseases.
Aerovance, Inc.
Berkeley, CA
Aerovance is a privately held biopharmaceutical company exclusively focused on the development and commercialization of biologics for respiratory and inflammatory diseases. The Company’s lead products are Aerovant™, an IL4/13 receptor antagonist for severe asthma and eczema that is currently in Phase II clinical studies, and Aeroderm, a novel therapeutic for eczema.
Fremont, CA
AFx, Inc. developed and marketed catheter-based, microwave ablation systems for minimally invasive treatment of major cardiac arrhythmias. AFx was acquired by Guidant in February of 2004.
Agensys, Inc.
Santa Monica, CA
Agensys discovered and developed therapeutic human monoclonal antibodies to treat solid tumor cancers based on its proprietary targets. The Company discovered and validated a large portfolio of novel clinically relevant targets in prostate, bladder, pancreatic and kidney cancer. Agensys was acquired by Astellas Pharma, Inc. in December of 2007.
La Jolla, CA
Angiosyn, Inc. is a biopharmaceutical company developing novel proprietary biologics for controlling angiogenesis. The company's initial therapeutic indication is for ophthalmic diseases, such as macular degeneration and diabetic retinopathy, which due to angiogenesis can lead to decreased vision and blindness. Angiosyn was acquired by Pfizer in January of 2005.
Arrow Therapeutics Ltd.
London, England
Arrow Therapeutics utilizes its genome-based target discovery technology to search for novel anti-microbial compounds. The Company is focused on unexplored targets for antibiotics, anti-viral, and anti-fungal therapies and aims to overcome the rapidly growing problem of microbial resistance.
Astex Pharmaceuticals, Inc.
Cambridge, England
Astex Pharmaceuticals™ is a leader in innovative drug discovery, development and commercialization, committed to the fight against cancer and other life-threatening diseases.
ATS Medical, Inc.
Minneapolis, Minnesota
ATS Medical, Inc. is a leading developer, manufacturer and marketer of products and services focused on cardiac surgery. Nasdaq: ATSI.
ATS was acquired by Medtronic in August of 2010.
Avid Radiopharmaceuticals, Inc.
Philadelphia, PA
Avid Radiopharmaceuticals is a leader in the development of molecular imaging products that allow for earlier and more effective detection, diagnosis and monitoring of major chronic human diseases. Avid was acquired by Eli Lilly (NYSE: LLY) in 2010.
Calistoga Pharmaceuticals
Seattle, Washington
Calistoga Pharmaceuticals is a drug discovery company focused on the development of products for the treatment of cancer and inflammatory diseases. Calistoga was acquired by Gilead Sciences, Inc. (Nasdaq: GILD) in 2011.
Cara Therapeutics, Inc.
Tarrytown, NY
Cara Therapeutics is a private, clinical stage company developing novel, first in class treatments for pain and inflammatory disorders. The Company’s most advanced programs are in the field of kappa opiate receptor agonists and cannabanoid receptor agonists and antagonists.
Cellective Therapeutics
Gaithersburg, MD
Cellective Therapeutics was a biopharmaceutical company focused on developing monoclonal antibodies for the treatment of oncology and autoimmune diseases such as B-cell lymphoma, Crohn’s disease and rheumatoid arthritis. The Company was founded in 2003 by Dr. Tom Tedder, Chairman of the Department of Immunology at Duke University, and based on technology licensed from Duke University and the Dana Farber Cancer Institute. Cellective was acquired by MedImmune in September of 2005.
Ceregene, Inc.
San Diego, CA
Using gene therapy delivery systems, Ceregene’s primary focus is the discovery and development of novel growth factor therapeutics for the treatment of neurological disorders. Ceregene has completed Phase I clinical trials in Alzheimer’s and Parkinson’s disease, and is currently conducting a double blind Phase II trial in Parkinson’s disease.
ChemGenex Pharmaceuticals
Melbourne, Australia and Menlo Park, CA
ChemGenex Pharmaceuticals is a pharmaceutical development company dedicated to improving the lives of patients by developing personalized therapeutics in the areas of oncology, diabetes and obesity. ChemGenex was acquired by Cephalon, Inc. in 2011.
ChemoCentryx, Inc.
MountainView, CA
ChemoCentryx is a focused pharmaceutical company engaged in drug discovery and development of first-in-class small molecule medicines targeting the chemokine system for autoimmune diseases, inflammatory disorders and oncology. ChemoCentryx’s most advanced clinical candidate, Traficet®, a CCR9 antagonist, is in Phase II studies for GI inflammatory indications.
Chimerix Inc.
Durham, North Carolina
Chimerix is a privately held drug development company which owns proprietary lipid prodrug technology to improve the efficacy of antiviral drugs. The Company’s lead compound, CMX001, is an active agent against a number of DNA viruses including smallpox and papilloma. Chimerix is also developing programs in CMV and HIV and is pursuing commercial opportunities to broaden the use of its technology.
Palo Alto, CA
Connetics Corporation (Nasdaq: CNCT) is a specialty pharmaceutical company focused on the development and commercialization of innovative therapeutics for the dermatology market.
Corcept Therapeutics, Inc.
Menlo Park, CA
Corcept Therapeutics is developing therapeutics for the treatment of severe psychiatric and neurological diseases. Specifically, Corcept is focused on the clinical development of a pharmaceutical compound, CORLUX, for the treatment of psychotic major depression (PMD). Nasdaq: CORT
CoTherix, Inc.
South San Francisco, CA
CoTherix is a biopharmaceutical company focused on licensing, developing and commercializing therapeutic products for the potential treatment of cardiopulmonary and other chronic diseases. CoTherix’s lead product, Ventavis (iloprost) was approved in December 2004 and launched in March 2005 for the treatment of pulmonary arterial hypertension, or PAH, in patients with New York Heart Association Class III or IV symptoms (WHO Group I). CoTherix was purchased by Actelion for $13.50 per share in 2006.
Nasdaq: CTRX
Leiden, The Netherlands
Crucell N.V. (Euronext, NASDAQ: CRXL; Swiss Exchange: SW CRX) is a biotechnology company focused on research, development and worldwide marketing of vaccines and antibodies that prevent and treat infectious diseases.
Burlingame, CA
Cutera, Inc.® (Nasdaq: CUTR) develops, manufactures, and markets laser hair removal systems for dermatologists, plastic surgeons and other practitioners in clinics and offices worldwide.
deCODE genetics
Reykjavik, Iceland
deCODE genetics (Nasdaq: DCGN) is a population-based genomics company conducting research into the inherited causes of common diseases. Together with pharmaceutical companies and other healthcare institutions, deCODE aims to utilize its research to develop new methods for identifying, treating and preventing disease.
Definity Health
Minneapolis, MN
Definity Health, founded in 1999, is a national market leader in consumer-driven health benefit programs. The company was acquired by UnitedHealth Group (NYSE: UNH) in December of 2004.
Londonderry, NH
Diatide, Inc. was founded as a private radiodiagnostic company and in 1999 became Diatide Research Laboratories, a division of Berlex Laboratories focused on developing and making specialized medicines. Diatide was a pioneer in the imaging marketplace, specializing in peptide engineering, molecular biology and radiolabeling chemistry to develop disease-specific diagnostic and therapeutic agents.
DiscoveRx Corp.
Fremont, CA
DiscoveRx® develops, manufactures, and commercializes reagents and complete assay kits for the drug discovery and screening markets. The Company’s products, biochemical and cell-based assays enable customers to improve research productivity and effectiveness, thus accelerating the discovery and development of new drugs.
Dynavax Technologies
Berkeley, CA
Dynavax Technologies (Nasdaq: DVAX) is a biopharmaceutical company developing products to treat allergy, inflammation-mediated diseases, infectious diseases and cancer. The Company's lead products are based on ImmunoStimulatory Sequences (ISS), short DNA sequences that enhance the ability of the immune system to fight disease and control chronic inflammation.
San Diego, CA
Endonetics, Inc. developed advanced, minimally invasive medical devices for the diagnosis and treatment of gastrointestinal disorders. The company was acquired by Medtronic, Inc. (MDT: NYSE) in December of 2001.
Esperion Therapeutics
Ann Arbor, MI
Esperion developed therapeutics for the treatment of cardiovascular diseases. in 2003, Pfizer agreed to buy Esperion for $1.3 billion.
Excaliard Pharmaceuticals
Encinitas, California
Excaliard is a private biotechnology company focused on the development and commercialization of antisense drugs for the local treatment of scarring and other fibrotic diseases.
Eyetech Pharmaceuticals
New York, NY
Eyetech Pharmaceuticals was founded to discover and develop new drugs to reduce and prevent serious vision loss caused by eye disease. Eyetech's lead product, EYE001, addresses the two leading causes of blindness in the adult population-age-related macular degeneration (AMD) and diabetic macular edema (DME). Eyetech was sold to OSI Pharmaceuticals in 2005.
Flamel Technologies
Cedex, France
Flamel Technologies S.A. (Nasdaq: FLML) is a biopharmaceutical company principally engaged in the development of two unique polymer-based delivery technologies for medical applications. Micropump® is a controlled release and taste-masking technology for the oral administration of small molecule drugs. Flamel's Medusa® technology is designed to deliver controlled-release formulations of therapeutic proteins.
FoldRx Pharmaceuticals, Inc.
Cambridge, MA
FoldRx Pharmaceuticals is a development and discovery company focusing on first-in-class, disease-modifying, small molecule therapeutics to treat diseases of protein misfolding and aggregation (amyloidosis). The Company’s lead product, FX-4006, has fully enrolled a Phase II/III study in familial amyloid polyneuropathy.
FoldRx was acquired by Pfizer in October of 2010
Guilford Pharmaceuticals
Baltimore, MD
Guilford Pharmaceuticals discovered, developed and marketed pharmaceutical products, targeting the hospital and neurological markets. The company was acquired by MGI Pharma (Nasdaq: MOGN), an oncology and acute care focused biopharmaceutical company, in October of 2005.
ILEX Oncology
San Antonio, TX
ILEX Oncology, Inc. was a drug development company focused exclusively on the accelerated development of drugs for the treatment and prevention of cancer. ILEX was acquired by Genzyme Corporation (Nasdaq: GENZ) in 2004.
Insulet Corporation
Bedford, MA
Insulet is commercializing the OmniPod Insulin Management System for diabetes patients.
Nasdaq: PODD
Brisbane, CA
Intermune, Inc. (Nasdaq: ITMN) is a biopharmaceutical company focused on developing and commercializing innovative therapies in hepatology and pulmonology. The company markets Actimmune® (interferon gamma-1b), approved for the treatment of severe, malignant steopetrosis and chronic granulomatous disease.
Kerberos Proximal Solutions, Inc.
Cupertino, California
Kerberos Proximal Solutions developed and commercialized innovative medical devices for the removal of thrombus from occluded arteries. The Company was acquired by FoxHollow Technologies (Nasdaq:FOXH) in August of 2006.
Kosan Biosciences, Inc.
Hayward, CA
Kosan Biosciences was an established cancer therapeutics company focused on advancing two new classes of anticancer agents through clinical development: heat shock protein 90 (Hsp90) inhibitors and epothilones.
Nasdaq: KOSN. Kosan was acquired by Bristol-Myers Squibb (BMY) in May of 2008.
LJL Biosystems
Sunnyvale, CA
LJL Biosystems, Inc. developed and manufactured automated instrumentation systems for clinical, research and drug development applications. The company was acquired by Molecular Devices Corporation (Nasdaq: MDCC) in August of 2000.
Lumena Pharmaceuticals
San Diego, CA
Lumena Pharmaceuticals is a privately-held biotechnology company developing oral therapeutics for rare liver diseases to improve liver function, relieve disease symptoms and dramatically impact patient health. The company’s clinical-stage product candidates carry a reduced risk of systemic toxicities by selectively targeting a transporter in the intestine and are designed to be minimally absorbed in the body. Lumena’s lead candidate, LUM001, has been extensively evaluated in other indications across 12 clinical studies in more than 1,400 subjects. Because of the extensive preclinical and clinical data package, LUM001 is positioned to rapidly progress through the clinic in pediatric and adult patients with several types of cholestatic liver disease.
MacroGenics, Inc.
Rockville, MD
MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer and autoimmune diseases. The company generates its pipeline of product candidates from its proprietary suite of next-generation antibody technology platforms, which it believes improve the performance of monoclonal antibodies and antibody-derived molecules. The company creates both differentiated molecules that are directed to novel cancer targets, as well as "bio-betters," which are drugs designed to improve upon marketed medicines. The combination of MacroGenics' technology platforms and antibody engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies.
MAKO Surgical
Ft. Lauderdale, FL
MAKO Surgical Corp. (Nasdaq:MAKO) is a medical device company focused on marketing its advanced robotic-arm solution and its implants for minimally invasive orthopedic knee procedures known as MAKOplasty®
Nanomix, Inc.
Emeryville, CA
Nanomix is a leading nanotechnology company launching a portfolio of devices based on Sensation™ detection technology. These scaleable, nanoelectronic devices use ultra-sensitive carbon nanotube sensing elements combined with proprietary chemistries. These devices can be deployed across a broad range of industrial and medical applications where the attributes of nanodetection technology - low power consumption, small form factor, and high sensitivity offer significant performance advantages and enable unprecedented access to critical information.
Nereus Pharmaceuticals, Inc.
San Diego, CA
Nereus Pharmaceuticals is a pioneer in the use of marine microbial sources for the discovery and follow-on development of new therapeutics for cancer and inflammatory and infectious diseases. The Company’s two oncology drug candidates are in Phase I clinical trials. NPI-2358, a tumor vascular disrupting agent, is being evaluated for solid tumors, and a proteasome inhibitor, NPI-0052, is being developed for solid tumors, lymphomas and multiple myeloma.
Onyx Pharmaceuticals
Richmond, CA
Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) is engaged in the development of novel cancer therapies that target the molecular basis of cancer. With its collaborators, the company is developing small molecule drugs, including Nexavar with Bayer Pharmaceuticals Corporation.
Orphan Medical
Minnetonka, MN
Orphan Medical is a specialty pharmaceutical company which acquires, develops, and markets pharmaceuticals for inadequately treated and uncommon diseases, including sleep disorders. The Company recently received regulatory approval in the United States for Xyrem, a therapeutic for the treatment of cataplexy. Orphan Medical was a public company traded on Nasdaq under the symbol ORPH. Orphan Medical was sold to Jazz Pharmaceuticals in 2005.
Pathwork Diagnostics
Redwood City, CA
Pathwork Diagnostics Inc. is a privately held company that develops and delivers innovative molecular diagnostics for oncology. Pathwork's Tissue of Origin Test identifies the source of cancers that are difficult to classify and increases oncologists’ confidence in their treatment approaches. It is the only FDA-approved molecular diagnostic test for tissue of origin.
Plexxikon, Inc.
Berkeley, CA
Plexxikon is a leader in the discovery and development of novel, small molecule pharmaceuticals. With its Scaffold-Based Drug Discovery Platform™, Plexxikon uses compound and target structural data to guide chemistry early in the drug lead generation process within various families of drug targets. The Company has clinical and preclinical stage programs in several therapeutic areas, including metabolic disease, oncology, inflammation, CNS and cardiovascular disease. Plexxikon was acquired by Daiichi Sankyo in 2011.
PneumRx, Inc.
Mountain View, CA
PneumRx is developing devices to address the unmet clinical needs in the interventional pulmonary/thoracic surgery market.
Portola Pharmaceuticals, Inc.
South San Francisco, CA
Portola Pharmaceuticals is dedicated to the discovery and development of innovative small molecule therapeutics for the prevention and treatment of thrombosis and cardiovascular disease. The Company is in Phase II trials with a Factor Xa inhibitor and an ADP receptor antagonist.
Proacta Therapeutics
San Diego, CA
Proacta Therapeutics is developing a new generation of cancer drugs that uniquely target physiological attributes of solid tumors. Proacta’s first lead program, a hypoxia targeted small-molecule prodrug, is designed to improve the outcomes of current treatment regimens, including chemotherapy and radio-therapy. Proacta is currently conducting a Phase II trial in small cell lung cancer.
Renovis, Inc.
South San Francisco, CA
Renovis discovers and develops biopharmaceuticals for the treatment of neurological and inflammatory diseases and disorders. The Company uses a combination of novel genomics and cell-based assay technologies coupled with expertise in neurobiology for the discovery of validated targets and the development of small molecules and protein therapeutics.
Nasdaq: RNVS
Rigel Pharmaceuticals
South San Francisco, CA
Rigel discovers and develops small molecule drugs based on its rapid drug target identification and validation technology. Rigel's technology is designed to identify and validate molecules which play an important role in regulating a human cell's response to disease. Rigel is currently testing its first product, a small molecule drug to treat allergic rhinitis, in clinical trials. Rigel is a public company that trades on Nasdaq under the symbol RIGL.
San Francisco, CA
SARcode is a venture-backed biopharmaceutical company focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/anti-inflammatory agents for the treatment of Tcell mediated inflammatory diseases. The Company’s lead program, targeting dry eye disease, is preparing to enter Phase III trials.
Silence Therapeutics
London, England
Silence Therapeutics possesses multiple RNAi discovery, development and delivery technologies, a broad internal and partnered product pipeline and a broad portfolio of intellectual property.
Sonexa Therapeutics, Inc.
San Diego, California
Sonexa Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of Alzheimer's disease.
Sunesis Pharmaceuticals, Inc.
South San Francisco, CA
Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the potential treatment of solid and hematologic cancers. Sunesis has built a highly experienced cancer drug development organization committed to improving the lives of people with cancer and is currently pursuing regulatory approval in Europe for its lead product candidate, vosaroxin, for the treatment of relapsed or refractory acute myeloid leukemia in patients aged 60 and older. In addition, the company is advancing its kinase-inhibitor pipeline of novel targeted therapies into the clinic. Nasdaq: SNSS
SurgRx, Inc.
Redwood City, CA
SurgRx developed and commercialized an advanced tissue sealing and hemostasis system. The Company was acquired by Ethicon Endo-Surgery, and Johnson & Johnson subsidiary, in October of 2008.
Syntonix Pharmaceuticals, Inc.
Waltham, MA
Syntonix Pharmaceuticals developed methods of pulmonary and potentially oral delivery of large molecules through a natural, readily accessible biological pathway, eliminating the need for injections and potentially reducing dosing frequency. The Company was acquierd by Biogen Idec in February of 2007.
Taligen Therapeutics, Inc.
Aurora, Colorado
Taligen is a development stage biotechnology company focused on the treatment of serious inflammatory diseases including asthma, macular degeneration and immune kidney disease. Taligen was acquired by Alexion Pharmaceuticals (NASDAQ: ALXN) in 2011
Palo Alto, CA
Telik, Inc. (Nasdaq: TELK) is a biopharmaceutical company dedicated to discovering, developing and commercializing novel small molecule drugs to treat cancer and other serious diseases.
The Medicines Company
Parsippany, NJ
The Medicines Company (Nasdaq: MDCO) meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care. The Company markets Angiomax® (bivalirudin) for injection, an anticoagulant approved for use in patients undergoing coronary angioplasty procedures.
Threshold Pharmaceuticals, Inc.
Redwood City, CA
Threshold is a clinical-stage biopharmaceutical company focused on the discovery and development of drugs and diagnostic agents targeting tumor hypoxia, the low oxygen condition found in microenvironments of most solid tumors as well as the bone marrows of some hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. Nasdaq: THLD
U3 Pharma AG
Martinsried, Germany
U3 Pharma AG was advancing a portfolio of novel antibody-based therapeutics to be used as mono therapies and combination therapies for the treatment of cancer. The two lead antibodies were potential therapies for breast, lung and colorectal cancers, among others. U3 Pharma was acquired by Daiichi-Sankyo in June of 2008
Copenhagen, Denmark
Veloxis (formerly LifeCycle Pharma) has developed a clinically validated drug-delivery platform for overcoming the deficiencies of drugs with low water-solubility, thus improving the bioavailability of marketed drugs and new chemical entities (NCEs). The Company’s clinical pipeline currently focuses on cardiovascular disease and immunosuppression. LCP has a diversified pipeline, including a product ready for US commercialization, five product candidates in clinical trials and three in preclinical stages of development.
Copenhagen Exchange: LCP.CO
Hertogenbosch, Netherlands
VitrOmics (formerly PamGene) develops valuable knowledge and tools in the field of Predictive Genomics. The necessary research are carried out by using in vitro exposure systems based on human cells and applying the latest genomics technologies.
Cambridge, MA
Zafgen is developing first in class drugs to treat obesity and related co-morbidities. The Company’s lead program, Beloranib is in Phase II clinical trials.
ZS Pharma, Inc.
Coppell, TX
ZS Pharma is a late-stage company developing a drug to treat Hyperkalemia. Hyperkalemia is a serious and potentially life-threating condition where one’s potassium levels become dangerously elevated causing arrhythmias and cardiac arrest. Hyperkalemia is most often seen in patients with chronic kidney disease (CKD) due to renal insufficiency and the condition is exacerbated by medications that these patients typically take (i.e. they increase serum potassium). In the U.S. alone there are approximately 25 million people with CKD and this number is expected to increase for the foreseeable future.